RPG Life Sciences LimitedQ2 FY27 Results & Financial Update
RPG Life Sciences Limited: Q2 FY27 consolidated results and company financials – revenue ₹211.64 Cr, PAT ₹28.22 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
RPG Life Sciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore RPG Life Sciences Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
RPG Life Sciences Limited reported consolidated revenue from operations of INR 211.64 crore for the quarter ended September 30, 2026, marking an increase compared to INR 195.69 crore in the preceding quarter (Q1 FY27).
Total income for Q2 FY27 stood at INR 215.90 crore, up from INR 200.39 crore in Q1 FY27, reflecting steady sequential top-line expansion.
Profit before tax (PBT) for the quarter was recorded at INR 37.04 crore, compared to INR 41.46 crore in the previous quarter, indicating a compression in pre-tax margins on a sequential basis.
Profit after tax (PAT) for Q2 FY27 came in at INR 28.22 crore, compared to INR 30.76 crore in Q1 FY27, translating to a PAT margin of 13.33% versus 15.72% in the preceding period.
Basic and diluted earnings per share (EPS) for the quarter stood at INR 17.07, compared to INR 18.60 reported in the first quarter of the fiscal year.
Total expenses during the quarter included depreciation and amortisation of INR 6.80 crore, finance costs of INR 0.84 crore, tax expenses of INR 8.82 crore, and provisions amounting to INR 9.80 crore.
Other income for the quarter contributed INR 4.26 crore to the financial results, alongside interest income of INR 5.89 crore.
01 · Business model
What does RPG Life Sciences do?
RPG Life Sciences Limited operates in the pharmaceuticals sector, engaged in the manufacturing and marketing of branded formulations and bulk drugs (APIs).
The company's operational model focuses on domestic formulations alongside international markets, serving both retail prescription drugs and specialized therapeutic segments.
Revenue generation is driven primarily by pharmaceutical product sales, supported by other operating income and interest income from treasury and financial assets.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹211.64 Cr | ₹195.69 Cr |
| Total income | ₹215.90 Cr | ₹200.39 Cr |
| Profit before tax | ₹37.04 Cr | ₹41.46 Cr |
| Profit after tax | ₹28.22 Cr | ₹30.76 Cr |
| EPS | ₹17.07 | ₹18.60 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 13.3% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 17.5% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹4.26 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations expanded to INR 211.64 crore in Q2 FY27 from INR 195.69 crore in Q1 FY27, representing an 8.15% sequential increase.
Total income reached INR 215.90 crore, bolstered by operational revenue alongside other income of INR 4.26 crore and interest income of INR 5.89 crore.
What drove margins
PAT margin softened to 13.33% in Q2 FY27 from 15.72% in Q1 FY27, representing a contraction of approximately 238 basis points sequentially.
The company incurred finance costs of INR 0.84 crore and depreciation charges of INR 6.80 crore during the quarter.
04 · Reported developments
What changed operationally
Operating revenue grew by 8.15% sequentially from INR 195.69 crore in Q1 FY27 to INR 211.64 crore in Q2 FY27.
05 · Pressure points & risks
What is not going smoothly
Net profit declined by 8.26% sequentially to INR 28.22 crore, leading to a contraction in PAT margin to 13.33%.
06 · Items worth noticing
The line items that can distort a quick read
The company recorded provisions amounting to INR 9.80 crore during the quarter.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
Consolidated Financial Filing
The financial results for Q2 FY27 were filed under consolidated scope via official exchange reporting channels.
08 · Previous-quarter changes
What changed since the previous quarter
Compared to Q1 FY27, revenue increased from INR 195.69 crore to INR 211.64 crore, while PAT moderated from INR 30.76 crore to INR 28.22 crore.
09 · Key Q&A
The quarter, answered directly
What does RPG Life Sciences do?
RPG Life Sciences Limited operates in the pharmaceuticals sector, engaged in the manufacturing and marketing of branded formulations and bulk drugs (APIs).
What is the clearest takeaway from Q2 FY27?
RPG Life Sciences Limited reported consolidated revenue from operations of INR 211.64 crore for the quarter ended September 30, 2026, marking an increase compared to INR 195.69 crore in the preceding quarter (Q1 FY27).
What drove revenue or demand?
Revenue from operations expanded to INR 211.64 crore in Q2 FY27 from INR 195.69 crore in Q1 FY27, representing an 8.15% sequential increase.
What mattered most for margins or profitability?
PAT margin softened to 13.33% in Q2 FY27 from 15.72% in Q1 FY27, representing a contraction of approximately 238 basis points sequentially.
What changed operationally beyond the headline numbers?
The financial results for Q2 FY27 were filed under consolidated scope via official exchange reporting channels.
What are the main pressure points disclosed for the quarter?
Net profit declined by 8.26% sequentially to INR 28.22 crore, leading to a contraction in PAT margin to 13.33%.
10 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
11 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Future Financial Disclosures: Monitor subsequent quarterly filings for operating margin trajectories and cost progression.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.